Cargando…

Test–retest repeatability of [(18)F]Flortaucipir PET in Alzheimer’s disease and cognitively normal individuals

The aim of this study was to investigate the test–retest (TRT) repeatability of various parametric quantification methods for [(18)F]Flortaucipir positron emission tomography (PET). We included eight subjects with dementia or mild cognitive impairment due to Alzheimer’s disease and six cognitively n...

Descripción completa

Detalles Bibliográficos
Autores principales:	Timmers, Tessa, Ossenkoppele, Rik, Visser, Denise, Tuncel, Hayel, Wolters, Emma E, Verfaillie, Sander CJ, van der Flier, Wiesje M, Boellaard, Ronald, Golla, Sandeep SV, van Berckel, Bart NM
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2019
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7705644/ https://www.ncbi.nlm.nih.gov/pubmed/31575335 http://dx.doi.org/10.1177/0271678X19879226

Ejemplares similares

Hippocampal [(18)F]flortaucipir BP(ND) corrected for possible spill-in of the choroid plexus retains strong clinico-pathological relationships
por: Wolters, Emma E, et al.
Publicado: (2019)

Effect of Shortening the Scan Duration on Quantitative Accuracy of [(18)F]Flortaucipir Studies
por: Tuncel, Hayel, et al.
Publicado: (2021)

Head-to-head comparison of relative cerebral blood flow derived from dynamic [(18)F]florbetapir and [(18)F]flortaucipir PET in subjects with subjective cognitive decline
por: Tuncel, Hayel, et al.
Publicado: (2023)

Longitudinal Tau PET Using (18)F-Flortaucipir: The Effect of Relative Cerebral Blood Flow on Quantitative and Semiquantitative Parameters
por: Visser, Denise, et al.
Publicado: (2023)

Regional [(18)F]flortaucipir PET is more closely associated with disease severity than CSF p-tau in Alzheimer’s disease
por: Wolters, Emma E., et al.
Publicado: (2020)

Associations between quantitative [(18)F]flortaucipir tau PET and atrophy across the Alzheimer’s disease spectrum
por: Timmers, Tessa, et al.
Publicado: (2019)

Repeatability of parametric methods for [(18)F]florbetapir imaging in Alzheimer’s disease and healthy controls: A test–retest study
por: Verfaillie, Sander CJ, et al.
Publicado: (2020)

Non-invasive Standardised Uptake Value for Verification of the Use of Previously Validated Reference Region for [(18)F]Flortaucipir and [(18)F]Florbetapir Brain PET Studies
por: de Vries, Bart M., et al.
Publicado: (2021)

Parametric methods for [(18)F]flortaucipir PET
por: Golla, Sandeep SV, et al.
Publicado: (2018)

Differential associations between neocortical tau pathology and blood flow with cognitive deficits in early-onset vs late-onset Alzheimer’s disease
por: Visser, Denise, et al.
Publicado: (2022)

A Head-to-Head Comparison Between Plasma pTau181 and Tau PET Along the Alzheimer’s Disease Continuum
por: Coomans, Emma M., et al.
Publicado: (2023)

[(18)F]Flortaucipir PET Across Various MAPT Mutations in Presymptomatic and Symptomatic Carriers
por: Wolters, Emma E., et al.
Publicado: (2021)

Quantification of [(18)F]florbetapir: A test–retest tracer kinetic modelling study
por: Golla, Sandeep SV, et al.
Publicado: (2018)

Tau pathology and relative cerebral blood flow are independently associated with cognition in Alzheimer’s disease
por: Visser, Denise, et al.
Publicado: (2020)

Precision estimates of relative and absolute cerebral blood flow in Alzheimer’s disease and cognitively normal individuals
por: Heeman, Fiona, et al.
Publicado: (2022)

Performance of a [(18)F]Flortaucipir PET Visual Read Method Across the Alzheimer Disease Continuum and in Dementia With Lewy Bodies
por: Coomans, Emma M., et al.
Publicado: (2023)

A novel partial volume correction method for accurate quantification of [(18)F] flortaucipir in the hippocampus
por: Wolters, Emma E., et al.
Publicado: (2018)

Kinetics and 28-day test–retest repeatability and reproducibility of [(11)C]UCB-J PET brain imaging
por: Tuncel, Hayel, et al.
Publicado: (2020)

Tau pathology as determinant of changes in atrophy and cerebral blood flow: a multi-modal longitudinal imaging study
por: Visser, Denise, et al.
Publicado: (2023)

Quantification of Tau Load Using [(18)F]AV1451 PET
por: Golla, Sandeep S. V., et al.
Publicado: (2017)

Classification of negative and positive (18)F-florbetapir brain PET studies in subjective cognitive decline patients using a convolutional neural network
por: de Vries, Bart Marius, et al.
Publicado: (2020)

Tau protein spreads through functionally connected neurons in Alzheimer’s disease: a combined MEG/PET study
por: Schoonhoven, Deborah N, et al.
Publicado: (2023)

Validation and test–retest repeatability performance of parametric methods for [(11)C]UCB-J PET
por: Tuncel, Hayel, et al.
Publicado: (2022)

Tau PET and relative cerebral blood flow in dementia with Lewy bodies: A PET study
por: Wolters, E.E., et al.
Publicado: (2020)

In vivo tau pathology is associated with synaptic loss and altered synaptic function
por: Coomans, Emma M., et al.
Publicado: (2021)

Cerebral blood flow, amyloid burden, and cognition in cognitively normal individuals
por: Ebenau, Jarith L., et al.
Publicado: (2022)

Why Is Amyloid-β PET Requested After Performing CSF Biomarkers?
por: Reimand, Juhan, et al.
Publicado: (2020)

Amyloid imaging in prodromal Alzheimer's disease
por: Ossenkoppele, Rik, et al.
Publicado: (2011)

Amyloid imaging in clinical trials
por: Ossenkoppele, Rik, et al.
Publicado: (2013)

Altered brain metabolism in frontotemporal dementia and psychiatric disorders: involvement of the anterior cingulate cortex
por: van Engelen, Marie-Paule E., et al.
Publicado: (2023)

Amyloid-β Load Is Related to Worries, but Not to Severity of Cognitive Complaints in Individuals With Subjective Cognitive Decline: The SCIENCe Project
por: Verfaillie, Sander C. J., et al.
Publicado: (2019)

Discordant amyloid-β PET and CSF biomarkers and its clinical consequences
por: de Wilde, Arno, et al.
Publicado: (2019)

Cerebral perfusion and glucose metabolism in Alzheimer’s disease and frontotemporal dementia: two sides of the same coin?
por: Verfaillie, Sander C. J., et al.
Publicado: (2015)

PET and CSF amyloid-β status are differently predicted by patient features: information from discordant cases
por: Reimand, Juhan, et al.
Publicado: (2019)

Longitudinal change in ATN biomarkers in cognitively normal individuals
por: Ebenau, Jarith L., et al.
Publicado: (2022)

Association of CSF, Plasma, and Imaging Markers of Neurodegeneration With Clinical Progression in People With Subjective Cognitive Decline
por: Ebenau, Jarith L., et al.
Publicado: (2022)

Test-retest variability of quantitative [(11)C]PIB studies in Alzheimer’s disease
por: Tolboom, Nelleke, et al.
Publicado: (2009)

Partial volume correction of brain PET studies using iterative deconvolution in combination with HYPR denoising
por: Golla, Sandeep S. V., et al.
Publicado: (2017)

ATN classification and clinical progression in subjective cognitive decline: The SCIENCe project
por: Ebenau, Jarith L., et al.
Publicado: (2020)

Design of the NL-ENIGMA study: Exploring the effect of Souvenaid on cerebral glucose metabolism in early Alzheimer's disease
por: Scheltens, Nienke M.E., et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_c67udneg603pi572fd1e1qu94h